Last reviewed · How we verify

NCT06794346

Sexual Effects of Transdermal or Vaginal Testosterone

Active, enrolled Phase 2 Last updated 27 January 2025
What this trial tests

Phase 2 trial testing Transdermal testosterone in Female Sexual Dysfunction in 132 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
1 October 2020
Primary endpoint
1 October 2024
1 November 2025

Quick facts

Lead sponsorUniversity of Sao Paulo General Hospital
PhasePhase 2
StatusActive, enrolled
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposetreatment
Enrollment132
Start date1 October 2020
Primary completion1 October 2024
Estimated completion1 November 2025
Sites1 location across Brazil

Drugs / interventions tested

Conditions studied

Sponsor

University of Sao Paulo General Hospital

Who can join

Adults 38 to 60, female only, with Female Sexual Dysfunction or Postmenopausal Symptoms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the study is to elucidate the role of testosterone treatment in postmenopausal women's sexual function and their therapeutic safety.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Female Sexual Dysfunction

Currently open trials in the same condition.

Other University of Sao Paulo General Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06794346.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing